---
document_datetime: 2026-02-12 15:12:38
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/retsevmo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: retsevmo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7365423
conversion_datetime: 2026-02-13 18:21:37.307272
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Retsevmo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | E.4 Change in the name and/or address of | 05/02/2026                          | 10/02/2026                                  | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315499                     | the marketing Term name: E.4 authorisation holder, ASMF holder, storage site of the master and/or working cell bank, manufacturing site for an active substance, intermediate or finished product, primary and/or secondary packaging site, manufacturer responsible for batch release, site where quality control takes place, and/or supplier of a packaging component, medical device (part), starting material, reagent and/or excipient (when mentioned in the dossier - E.4.a) The change in the name and/or address concerns the marketing authorisation holder - Accepted   |            |            | Labelling and PL   |           |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------|
| PSUR / EMA/PSUR/0000288253            | In view of available data on Stevens- Johnson syndrome (SJS) from the literature, including a close temporal relationship in 1 case from literature , and a diagnosis based on clinical picture together with histopathological findings, the PRAC Rapporteur considers a causal relationship between selpercatinib and Stevens-Johnson syndrome is at least a reasonable possibility. The PRAC Rapporteur concluded that the product information of products containing selpercatinib should be amended accordingly                                                                | 11/12/2025 | 10/02/2026 | SmPC and PL        | Variation |
| Variation type IA / EMA/VR/0000312896 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/11/2025 |            |                    |           |

<div style=\"page-break-after: always\"></div>

| Renewal - 1 year / EMA/R/0000286890   | Renewal of conditional marketing authorisation                                                                                                                                                                                                                                                                                                                     | 16/10/2025   | 12/12/2025   | SmPC and Annex II   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Retsevmo, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. Section 5.1 of the SmPC have been revised to reflect the updated efficacy data available from LIBRETTO-001 study with data cut-off of 14 February 2025.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000278785 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                              | 08/09/2025   |              |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Variation type II / EMA/VR/0000247142 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.b Implementation of change(s) which require | 10/04/2025   | 12/12/2025   | SmPC                | Section 5.3 Long-term studies to assess the carcinogenic potential of selpercatinib have not been performed.In a 2-year carcinogenicity study of selpercatinib in rats, vaginal tumours were observed in some females at plasma exposure levels similar to levels observed in adult patients treated with the dose of 160mg twice daily. No pre -neoplastic changes were observed in the reproductive tract of female rats. The clinical relevance of these findings                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                            | to be further substantiated by new additional data to be submitted by the MAH - Accepted Update of section 5.3 of the SmPC in order to update information on carcinogenesis based on results from a non-clinical 2-year carcinogenicity study of selpercatinib in rats. The RMP version 14.2 has also been submitted.   | is unknown. Selpercatinib was not carcinogenic in male rats in this study. Selpercatinib was not carcinogenic in male and female mice in a 6-month study.                                                                                           |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248503 |                                                                                                                                                                                                                                                                                                                         | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing selpercatinib remains unchanged and therefore recommends the maintenance of the marketing authorisation. |